Page last updated: 2024-09-03

tazobactam and imipenem, anhydrous

tazobactam has been researched along with imipenem, anhydrous in 103 studies

Compound Research Comparison

Studies (tazobactam)	Trials (tazobactam)	Recent Studies (post-2010) (tazobactam)	Studies (imipenem, anhydrous)	Trials (imipenem, anhydrous)	Recent Studies (post-2010) (imipenem, anhydrous)
1,327	153	694	4,784	391	1,397

Protein Interaction Comparison

Protein	Taxonomy	tazobactam (IC50)	imipenem, anhydrous (IC50)
Beta-lactamase	Pseudomonas aeruginosa		0.15

Research

Studies (103)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	18 (17.48)	18.2507
2000's	32 (31.07)	29.6817
2010's	24 (23.30)	24.3611
2020's	29 (28.16)	2.80

Authors

Authors	Studies
Bonnet, R; Chanal, C; Delmas, J; Lesens, O; Robin, F; Schweitzer, C; Tournilhac, O	1
Aubert, D; Naas, T; Nordmann, P; Ozcan, A	1
Arlet, G; Loli, A; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS	1
Cattoir, V; Corvec, S; Drugeon, H; Faccone, D; Galas, M; Mugnier, P; Nordmann, P; Pasteran, F; Petroni, A; Poirel, L; Rapoport, M	1
Ayala, JA; Casellas, JM; Di Conza, J; Ghiglione, B; Gutkind, G; Power, P; Radice, M; Rodríguez, MM	1
Amicosante, G; Caporale, B; Celenza, G; Docquier, JD; Mezzatesta, M; Pellegrini, C; Perilli, M; Rossolini, GM; Stefani, S	1
Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS	1
Bonnet, R; Brebion, A; Constantin, JM; Delmas, J; Dubois, D; Robin, F	1
Girlich, D; Leclercq, R; Naas, T; Nordmann, P	1
Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J	1
Bonnet, R; Neuwirth, C; Robin, F; Siebor, E	1
Courvalin, P; Decré, D; Høiby, EA; Meziane-Cherif, D; Périchon, B	1
Courvalin, P; Dupêchez, M; Galimand, M; Lambert, T; Meziane-Cherif, D	1
Bonnet, R; Caniça, M; Ferreira, E; Manageiro, V; Mendonça, N; Robin, F; Salgado, MJ	1
Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR	1
Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M	1
Andlovic, A; Jeverica, S; Karisik, E; Koren, S; Krizan-Hergouth, V; Livermore, DM; Mesko Meglic, K; Müller-Premru, M; Palepou, MF; Pike, R; Seme, K; Woodford, N	1
Nordmann, P; Plésiat, P; Poirel, L; Rodriguez-Martinez, JM	1
Bonnet, R; Brisabois, A; Cloeckaert, A; Doublet, B; Fabre, L; Granier, SA; Robin, F; Weill, FX	1
Kirikae, T; Kitao, T; Miyoshi-Akiyama, T	1
Chanteperdrix, V; Croizé, J; Nordmann, P; Poirel, L; Potron, A	1
Kotsakis, SD; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS	1
Ghori, S; Griggs, DJ; Johnson, MM; Mott, A; Peake, L; Piddock, LJ	1
Bonnet, R; Casin, I; Doublet, B; Fabre, L; Le Fleche, A; Robin, F; Weill, FX	1
De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A	1
Girlich, D; Nordmann, P; Poirel, L	1
Bethel, CR; Bonomo, RA; Distler, AM; Kasuboski, C; Papp-Wallace, KM; Taracila, M	1
Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS	1
Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH	1
Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M	1
Chan, MC; Chang, TY; Chiueh, TS; Sun, JR; Wang, WY	1
Kotsakis, SD; Miriagou, V; Tzelepi, E; Tzouvelekis, LS	1
Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R	1
Martin, NI; Tehrani, KHME	1
Spencer, RC; Wilcox, MH; Winstanley, TG	1
Bäckstrand, B; Bergman, L; Brismar, B; Kihlström, E; Malmborg, AS; Mentzing, LO; Nyström, PO; Skau, T; Tunevall, G; Wretlind, B	1
Blakemore, PH; Drabu, YJ; Mehtar, S	1
Lahnborg, G; Nord, CE	1
Cony Makhoul, P; Darmaillac, V; Fourche, J; Maugein, J; Perrier, F	1
Jones, R; Satishchandran, V; Shapiro, T; Suh, B; Truant, AL	1
Alhava, E; Haapiainen, R; Havia, T; Kivilaakso, E; Laitinen, S; Matikainen, M; Miettinen, P; Niinikoski, J; Pääkkönen, M	1
Eklund, AE; Nord, CE	1
Palmer, SM; Rybak, MJ	1
Chen, HY; Livermore, DM	1
Adhikari, M; Pillay, DG; Pillay, T; Sturm, AW	1
Bryce, E; Frighetto, L; Jewesson, P; MacDougall, C; Marra, F; Reynolds, R; Sleigh, K; Stiver, G	1
Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N	1
Ambrosetti, P; Aymon, D; Bille, J; Chiolero, R; Cometta, A; Glauser, MP; Harbarth, S; Huber, O; Jaccard, C; Lew, D; Praz, G; Ricou, B; Romand, J; Schneider, R; Troillet, N; Zanetti, G	1
Bryce, EA; Frighetto, LO; Jewesson, PJ; Marra, CA; Marra, FO; Reynolds, RP; Sleigh, KM; Stiver, HG	1
Betriu, C; Gómez, M; Palau, ML; Picazo, JJ; Sánchez, A	1
Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I	1
Kays, MB	1
Naber, KG; Salmen, HC; Savov, O	1
Jones, RN; Mutnick, AH; Turner, PJ	1
Crisostomo, AC; Erasmo, AA; Hong, YS; Lee, KU; Lo, CM; Yan, LN	1
Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M	1
Bermúdez, A; Besalduch, J; Nocea, G; Pascual, MJ; Rovira, M; Sanz, MA; Sanz-Rodríguez, C	1
Cooper, A; Joshi, M; Kassira, W; McCarthy, M; Metzler, M; Olvey, S	1
Leitner, E; Lode, H; Schmitt, DV; Welte, T	1
Bennett, KM; Dodds-Ashley, E; Hayward, TZ; Kaye, KS; Scarborough, JE; Sharpe, M; Vaslef, SN	1
Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L	1
Dundar, D; Otkun, M	1
Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A	1
Chin, K; Haruna, A; Ichiyama, S; Ito, I; Kadowaki, S; Kase, M; Matsumoto, H; Mishima, M; Nakai, A; Niimi, A; Tanabe, N; Tsukino, M; Yasutomo, Y	1
Funke, M; Janssen, E; Rodloff, AC; Schaumann, R	1
Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V	1
Dortet, L; Nordmann, P; Poirel, L	1
Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L	1
Chong, Y; Jeong, SH; Kim, M; Kim, WH; Lee, K; Lee, Y; Seo, YH; Yim, J; Yong, D	1
Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J	1
Ali, I; Shabbir, M	1
Hsueh, PR; Hsueh, SC; Huang, YT; Lee, YJ; Liao, CH; Tsuji, M	1
Barnes, SW; Dean, CR; Iartchouk, O; Jones, AK; Lee, PS; Mostafavi, M; Ranjitkar, S; Walker, JR; Willis, TW; Zwirko, Z	1
Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P	1
Aboklaish, AF; Brem, J; Jackson, DE; Langley, GW; Schofield, CJ; Tselepis, L; Tyrrell, JM; Walsh, TR; Widlake, E	1
Cabot, G; Fernández-Esgueva, M; Fraile-Ribot, PA; Huarte, R; López-Calleja, AI; Mulet, X; Oliver, A; Rezusta, A	1
DePestel, DD; Karlowsky, JA; Lob, SH; Motyl, MR; Raddatz, J; Sahm, DF; Young, K	1
Al-Hasan, MN	1
Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H	1
Canovas, J; Chau, F; Fantin, B; Le Monnier, A; Lefort, A; Petitjean, G	1
Boucher, HW; Brown, ML; Butterton, JR; Chen, LF; David-Wang, A; Du, J; Kartsonis, NA; Kaye, KS; Losada, MC; Paschke, A; Patel, M; Rizk, ML; Rodríguez Gonzalez, D; Roquilly, A; Tipping, R; Titov, I; Wunderink, RG; Young, K	1
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A	1
He, A; He, L; Qian, Y	1
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E	1
Carvalhaes, CG; Castanheira, M; Sader, HS; Shortridge, D	1
Castanheira, M; Duncan, LR; Mendes, RE; Sader, HS	1
Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF	1
Cabot, G; Gomis-Font, MA; Juan, C; López-Argüello, S; Moyá, B; Oliver, A; Zamorano, L	1
DeRyke, CA; Hilbert, DW; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Wong, MT; Young, K	1
Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A	1
Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Cabot, G; Fraile-Ribot, PA; Galán-Sánchez, F; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Oliver, A; Rumbo-Feal, S; Vázquez-Ucha, JC	1
Amoureux, L; Casenaz, A; Guilloteau, A; Labattut, L; Magallon, A; Neuwirth, C; Piroth, L; Sixt, T	1
Azam, N; Cherkaoui, A; Crudeli, L; Fernandez, J; Fischer, A; Renzi, G; Schorderet, D; Schrenzel, J	1
Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y	1
Haines, RR; Hammer, KA; Putsathit, P; Tai, AS	1
Alekseeva, I; DeRyke, CA; Hawser, SP; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K	1
Cabot, G; Khajehpour, M; Kim, K; Mark, BL; Oliver, A	1
Arends, SJR; Carvalhaes, CG; Castanheira, M; Mendes, RE; Sader, HS; Shortridge, D	1
Aja-Macaya, P; Alonso-García, I; Arca-Suárez, J; Beceiro, A; Bou, G; Fernández-González, A; Galán-Sánchez, F; González-Mayo, E; Guijarro-Sánchez, P; Lada-Salvador, P; Lasarte-Monterrubio, C; Martínez-Guitián, M; Muíño-Andrade, M; Oliver, A; Rodríguez-Iglesias, M; Rumbo-Feal, S; Vázquez-Ucha, JC; Vela-Fernández, R	1
Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K	1
Hsueh, PR; Ko, WC; Lee, YL	1
Chen, WT; DeRyke, CA; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K	1
Ali Khan, H; Amir, M; Ammad, M; Anjum, S; Arshad, N; Faryal, R; Khadija, B; Mazhar, K; Noorul Hasan, T; Rashid, Z; Sajjad Naqvi, S; Ullah, R; Ur Rehman, M; Yousaf, M	1

Reviews

3 review(s) available for tazobactam and imipenem, anhydrous

Article	Year
β-lactam/β-lactamase inhibitor combinations: an update. MedChemComm, 2018, Sep-01, Volume: 9, Issue:9 Topics:	2018
The role of new antimicrobials for Gram-negative infections in daily clinical practice. Current opinion in infectious diseases, 2020, Volume: 33, Issue:6 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines	2020
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. International journal of antimicrobial agents, 2021, Volume: 57, Issue:5 Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin	2021

Trials

14 trial(s) available for tazobactam and imipenem, anhydrous

Article	Year
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrobial agents and chemotherapy, 1992, Volume: 36, Issue:12 Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome	1992
Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surgery, gynecology & obstetrics, 1993, Volume: 176, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Female; Humans; Imipenem; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Peritoneal Diseases; Piperacillin; Tazobactam; Treatment Outcome	1993
A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. The Journal of antimicrobial chemotherapy, 1993, Volume: 31 Suppl A Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactamase Inhibitors; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Injections, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam	1993
Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagnostic microbiology and infectious disease, 1998, Volume: 31, Issue:2 Topics: Adolescent; Adult; beta-Lactamase Inhibitors; Cost-Benefit Analysis; Double-Blind Method; Drug Therapy, Combination; Feasibility Studies; Female; Hospitals, Teaching; Humans; Imipenem; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Thienamycins; Treatment Outcome	1998
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:11 Topics: Acute Disease; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam	1998
Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective. The Annals of pharmacotherapy, 1999, Volume: 33, Issue:2 Topics: Adult; Anti-Infective Agents; Bacterial Infections; British Columbia; Cilastatin; Costs and Cost Analysis; Decision Trees; Double-Blind Method; Drug Therapy, Combination; Economics, Pharmaceutical; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Models, Economic; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Protease Inhibitors; Statistics, Nonparametric; Tazobactam; Thienamycins; Treatment Outcome	1999
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. International journal of antimicrobial agents, 2002, Volume: 19, Issue:2 Topics: Adolescent; Adult; Aged; Cilastatin; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Pyelonephritis; Sample Size; Tazobactam; Thienamycins; Urinary Tract Infections	2002
Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection. Asian journal of surgery, 2004, Volume: 27, Issue:3 Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Cilastatin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam	2004
Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study. Current medical research and opinion, 2005, Volume: 21, Issue:5 Topics: Adult; Amikacin; Anti-Bacterial Agents; Cilastatin; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Male; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Protease Inhibitors; Spain; Tazobactam; Treatment Outcome	2005
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respiratory medicine, 2006, Volume: 100, Issue:9 Topics: Anti-Bacterial Agents; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Protease Inhibitors; Tazobactam; Tobramycin; Treatment Outcome	2006
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study. Infection, 2006, Volume: 34, Issue:3 Topics: Adult; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam; Treatment Outcome	2006
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin. Pulmonary pharmacology & therapeutics, 2010, Volume: 23, Issue:5 Topics: Aged, 80 and over; Anti-Bacterial Agents; Cilastatin; Community-Acquired Infections; Drug Combinations; Female; Humans; Imipenem; Injections, Intravenous; Male; Nursing Homes; Penicillanic Acid; Piperacillin; Pneumonia, Aspiration; Prospective Studies; Protease Inhibitors; Tazobactam; Treatment Outcome	2010
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 12-06, Volume: 73, Issue:11 Topics: Adult; Aged; Anti-Bacterial Agents; Azabicyclo Compounds; Cilastatin; Hospitals; Humans; Imipenem; Piperacillin; Tazobactam; Ventilators, Mechanical	2021
Fully Automated EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) from Positive Blood Cultures: Diagnostic Accuracy and Implementation. Journal of clinical microbiology, 2022, 10-19, Volume: 60, Issue:10 Topics: Anti-Bacterial Agents; beta-Lactamases; Blood Culture; Cefepime; Ceftazidime; Humans; Imipenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Prospective Studies; Tazobactam	2022

Other Studies

86 other study(ies) available for tazobactam and imipenem, anhydrous

Article	Year
Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: beta-Lactamases; Drug Resistance, Bacterial; Escherichia coli; Evolution, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation	2007
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: beta-Lactamases; Chromosomes; Chromosomes, Bacterial; Citrobacter; Cloning, Molecular; DNA, Bacterial; Escherichia coli; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Molecular Sequence Data	2007
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6 Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillinase; Plasmids; Sequence Analysis, DNA	2007
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6 Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Clavulanic Acid; Cloning, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA	2007
Biochemical characterization of PER-2 and genetic environment of blaPER-2. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Amino Acid Sequence; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Catalysis; Citrobacter freundii; Conjugation, Genetic; DNA, Bacterial; DNA, Recombinant; Enterobacteriaceae; Genes, Bacterial; Humans; Hydrolysis; Isoelectric Focusing; Kinetics; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Plasmids; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Conformation; Protein Sorting Signals; Sequence Analysis, DNA	2007
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8 Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporins; Chryseobacterium; Flavobacteriaceae Infections; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Sequence Analysis, DNA	2007
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10 Topics: Anti-Bacterial Agents; Cephalosporinase; Culture Media; DNA Primers; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Models, Molecular; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry, Ultraviolet	2007
TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Catalysis; Ceftazidime; Clavulanic Acid; Escherichia coli; Escherichia coli Proteins; Isoenzymes; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA	2007
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: Amino Acid Sequence; Bacillus; Bacterial Proteins; beta-Lactamases; Chromosome Mapping; Chromosomes, Bacterial; Cloning, Molecular; Microbial Sensitivity Tests; Molecular Sequence Data; Molecular Weight; Sequence Homology, Amino Acid; Substrate Specificity	2007
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12 Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam	2007
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12 Topics: Aeromonas; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; France; Integrons; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA; Substrate Specificity	2007
Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:2 Topics: Amino Acid Sequence; beta-Lactams; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Infant, Newborn; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillin Resistance; Penicillinase; Sequence Alignment; Sequence Analysis, DNA; Substrate Specificity	2008
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Brachyspira; Cloning, Molecular; Diarrhea; Feces; Gram-Negative Bacterial Infections; Humans; Kinetics; Molecular Sequence Data; Oxacillin; Penicillin Resistance; Sequence Analysis, DNA	2008
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5 Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Arginine; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Computer Simulation; Imipenem; Isoelectric Focusing; Kinetics; Klebsiella pneumoniae; Lysine; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Penicillins; Protein Conformation; Protein Structure, Tertiary	2008
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8 Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity	2008
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure	2008
Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Anti-Bacterial Agents; beta-Lactamases; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Klebsiella pneumoniae; Microbial Sensitivity Tests; Slovenia	2009
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Alleles; Amino Acid Sequence; Amino Acid Substitution; Base Sequence; beta-Lactamases; Burkholderia cepacia complex; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Hydrolysis; Isoelectric Point; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid	2009
Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5 Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cardiidae; Ceftazidime; Ceftriaxone; Cephalosporin Resistance; Electrophoresis, Gel, Pulsed-Field; France; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Salmonella enterica; Serotyping	2009
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6 Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa	2009
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7 Topics: Acinetobacter baumannii; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed	2009
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Cephalosporins; Escherichia coli Proteins; Protein Binding; Protein Structure, Secondary	2009
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:8 Topics: Amino Acid Sequence; Amoxicillin; Ampicillin; Animals; Anti-Bacterial Agents; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Blotting, Southern; Campylobacter jejuni; Carbenicillin; Cephalosporins; Chickens; Cloxacillin; Isoelectric Focusing; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Piperacillin; Polymerase Chain Reaction; Sequence Alignment; Ticarcillin	2009
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Catheters, Indwelling; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genetic Variation; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Pseudomonas; Pseudomonas Infections; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Substrate Specificity	2010
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections	2010
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; France; Fresh Water; Gram-Negative Bacteria; Health Surveys; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas fluorescens; Water Microbiology	2010
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2 Topics: Anti-Bacterial Agents; beta-Lactamases; Catalytic Domain; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Kinetics; Microbial Sensitivity Tests; Penicillanic Acid; Spectrometry, Mass, Electrospray Ionization; Sulbactam; Tazobactam	2010
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3 Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA	2010
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea	2010
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam	2010
Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Male; Membrane Transport Proteins; Middle Aged; Minocycline; Molecular Sequence Data; Mutagenesis, Insertional; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline	2010
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Ampicillin; beta-Lactamases; Computational Biology; Escherichia coli; Hydrogen Bonding; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Protein Structure, Secondary; Ticarcillin	2010
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9 Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship	2015
Effect of pH on antibiotics used to treat anaerobic infection. The Journal of antimicrobial chemotherapy, 1992, Volume: 29, Issue:5 Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Cefoxitin; Clindamycin; Drug Therapy, Combination; Hydrogen-Ion Concentration; Imipenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam	1992
The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria. The Journal of antimicrobial chemotherapy, 1990, Volume: 25, Issue:6 Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Serratia; Tazobactam	1990
Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections. The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 1994, Issue:573 Topics: Abdomen; Animals; Bacterial Infections; beta-Lactamase Inhibitors; Clindamycin; Drug Therapy, Combination; Gentamicins; Imipenem; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rats; Rats, Sprague-Dawley; Tazobactam	1994
[In vitro activity of six beta-lactams against 295 strains of enterobacteriaceae and P. aeruginosa isolated from neutropenic patients]. Pathologie-biologie, 1995, Volume: 43, Issue:4 Topics: Cefepime; Cefotaxime; Cefpirome; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Neutropenia; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins	1995
In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagnostic microbiology and infectious disease, 1995, Volume: 21, Issue:2 Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Cefotaxime; Ceftazidime; Ceftriaxone; Clavulanic Acid; Clavulanic Acids; Colony Count, Microbial; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Sulbactam; Tazobactam	1995
An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin The Journal of antimicrobial chemotherapy, 1997, Volume: 39, Issue:4 Topics: Ampicillin; Anti-Bacterial Agents; Drug Synergism; Drug Therapy, Combination; Fibrin; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests; Nafcillin; Penicillanic Acid; Penicillins; Piperacillin; Staphylococcus aureus; Sulbactam; Tazobactam; Vancomycin	1997
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:3 Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Tazobactam; Thienamycins	1997
Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. American journal of perinatology, 1998, Volume: 15, Issue:1 Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cilastatin; Ciprofloxacin; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Imipenem; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Protease Inhibitors; Retrospective Studies; Tazobactam; Thienamycins	1998
Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet (London, England), 1998, Aug-15, Volume: 352, Issue:9127 Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom	1998
In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents. The Journal of antimicrobial chemotherapy, 1999, Volume: 43, Issue:1 Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacteroides fragilis; beta-Lactamase Inhibitors; Cefoxitin; Ceftizoxime; Chloramphenicol; Clavulanic Acid; Clindamycin; Drug Therapy, Combination; Enzyme Inhibitors; Imipenem; Metronidazole; Mezlocillin; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Species Specificity; Sulbactam; Tazobactam; Thienamycins; Ticarcillin	1999
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group. Wiener klinische Wochenschrift, 1999, Jul-30, Volume: 111, Issue:14 Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins	1999
Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances. Pharmacotherapy, 1999, Volume: 19, Issue:12 Topics: Anti-Bacterial Agents; Bacteria; Cefepime; Ceftazidime; Cephalosporins; Creatinine; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Time Factors	1999
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:3 Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins	2002
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens]. Medycyna doswiadczalna i mikrobiologia, 2004, Volume: 56, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin	2004
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. The Journal of trauma, 2007, Volume: 63, Issue:2 Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Incidence; Intensive Care Units; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Probability; Retrospective Studies; Sensitivity and Specificity; Tazobactam; Treatment Outcome	2007
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins	2009
In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei medical journal, 2010, Volume: 51, Issue:1 Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tobramycin	2010
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators. Critical care (London, England), 2010, Volume: 14, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome	2010
In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Anti-Infective Agents; Bacteroides fragilis; Clindamycin; Imipenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam	2012
Class A carbapenemase FPH-1 from Francisella philomiragia. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins	2012
Rapid identification of carbapenemase types in Enterobacteriaceae and Pseudomonas spp. by using a biochemical test. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:12 Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cost-Benefit Analysis; Drug Resistance, Multiple, Bacterial; Edetic Acid; Enterobacteriaceae; Hydrolysis; Imipenem; Penicillanic Acid; Pseudomonas; Reproducibility of Results; Tazobactam; Zinc Sulfate	2012
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6 Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins	2014
Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital. Annals of laboratory medicine, 2015, Volume: 35, Issue:1 Topics: Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Inhibitory Concentration 50; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Republic of Korea; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Tertiary Care Centers; Thienamycins	2015
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory. BMC infectious diseases, 2017, 01-17, Volume: 17, Issue:1 Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin	2017
Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Imipenem; Infant; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Sulbactam; Tazobactam; Urinary Tract Infections; Young Adult	2017
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream The Journal of antimicrobial chemotherapy, 2019, 02-01, Volume: 74, Issue:2 Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Taiwan; Tazobactam	2019
Target (MexB)- and Efflux-Based Mechanisms Decreasing the Effectiveness of the Efflux Pump Inhibitor D13-9001 in Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:2 Topics: beta-Lactams; Imipenem; Microbial Sensitivity Tests; Monobactams; Piperidines; Pseudomonas aeruginosa; Quaternary Ammonium Compounds; Tazobactam; Thienamycins; Transcriptome	2019
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion. Die Pharmazie, 2019, 06-01, Volume: 74, Issue:6 Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam	2019
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. International journal of antimicrobial agents, 2020, Volume: 56, Issue:1 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cefepime; Drug Combinations; Enterobacteriaceae Infections; Humans; Imipenem; Microbial Sensitivity Tests; Tazobactam; Triazoles	2020
Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades infecciosas y microbiologia clinica (English ed.), 2020, Volume: 38, Issue:10 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2020
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United State Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 06-15, Volume: 72, Issue:12 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Phenotype; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States	2021
Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 06-15, Volume: 72, Issue:12 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Drug Resistance, Bacterial; Gram-Negative Bacteria; Imipenem; Phenotype; Tazobactam	2021
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany. International journal of antimicrobial agents, 2020, Volume: 55, Issue:6 Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2020
Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020, Volume: 26, Issue:10 Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cephalosporins; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Imipenem; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Peritonitis; Tazobactam	2020
Imipenem-resistant Pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review. Annals of palliative medicine, 2021, Volume: 10, Issue:1 Topics: Aged; Female; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Tazobactam	2021
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022, Volume: 41, Issue:2 Topics: Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Hospitalization; Humans; Imipenem; Jupiter; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2022
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021, Volume: 113 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Boronic Acids; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Tazobactam	2021
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales. Diagnostic microbiology and infectious disease, 2022, Volume: 102, Issue:1 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam	2022
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. The Journal of antimicrobial chemotherapy, 2022, 03-31, Volume: 77, Issue:4 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Cephalosporins; Clone Cells; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2022
Antimicrobial agents and chemotherapy, 2022, 05-17, Volume: 66, Issue:5 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; United States	2022
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:11 Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam	2022
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. The Journal of antimicrobial chemotherapy, 2022, 09-30, Volume: 77, Issue:10 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Borinic Acids; Carboxylic Acids; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Cyclooctanes; Humans; Imipenem; Piperidines; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2022
Epidemiology and antibiotic resistance of prosthetic joint infections according to time of occurrence, a 10-year study. The Journal of infection, 2022, Volume: 85, Issue:5 Topics: Anti-Bacterial Agents; Arthritis, Infectious; Cefotaxime; Coagulase; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Prosthesis-Related Infections; Retrospective Studies; Staphylococcus aureus; Tazobactam; Vancomycin	2022
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. BMC microbiology, 2022, 10-01, Volume: 22, Issue:1 Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline	2022
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. Scientific reports, 2022, 10-07, Volume: 12, Issue:1 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2022
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2023, Volume: 42, Issue:3 Topics: Anti-Bacterial Agents; Cephalosporins; Czech Republic; Humans; Hungary; Imipenem; Microbial Sensitivity Tests; Poland; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2023
Biochemical Insights into Imipenem Collateral Susceptibility Driven by Antimicrobial agents and chemotherapy, 2023, 02-16, Volume: 67, Issue:2 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2023
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). International journal of antimicrobial agents, 2023, Volume: 61, Issue:4 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporins; Drug Combinations; Hospitals; Humans; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2023
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections. The Journal of antimicrobial chemotherapy, 2023, 05-03, Volume: 78, Issue:5 Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Ceftazidime; Cephalosporinase; Cephalosporins; Drug Combinations; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020. Journal of global antimicrobial resistance, 2023, Volume: 33 Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam	2023
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil International journal of antimicrobial agents, 2023, Volume: 62, Issue:2 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam	2023
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020. International journal of antimicrobial agents, 2023, Volume: 62, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thailand	2023
Presence of T3SS (exoS, exoT, exoU and exoY), susceptibility pattern and MIC of MDR-Pseudomonas aeruginosa from burn wounds. Journal of infection in developing countries, 2023, 08-31, Volume: 17, Issue:8 Topics: Anti-Bacterial Agents; Colistin; Hospitals, Teaching; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Tazobactam	2023